Emergent BioSolutions Inc. revised earnings guidance for the year 2022. For the year, the company expects revised total revenues to be in the range of $1,050 million to $1,100 million compared to previously expected total revenues to be in the range of $1,150 million to $1,250 million. Net loss to be in the range of $217 million to $189 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.95 USD | -10.55% | +4.84% | -18.75% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.75% | 102M | |
+25.67% | 556B | |
-6.33% | 354B | |
+19.90% | 331B | |
+7.95% | 296B | |
+13.19% | 233B | |
+5.40% | 201B | |
-9.86% | 193B | |
-12.26% | 143B | |
-6.47% | 144B |
- Stock Market
- Equities
- EBS Stock
- News Emergent BioSolutions Inc.
- Emergent BioSolutions Inc. Revises Earnings Guidance for the Year 2022